DOT-EPR-Header

One of the most recent yet exciting areas of discovery research centers around targeting chromatin modifying proteins, particularly those responsible for the recognition of the histone code written in acetyl and methyl marks. With several clinical trials underway, and countless discovery programs initiated, particular interest has been given to targeting the bromodomain family of proteins across a diverse range of therapeutic indications. Advances in probe development allows for individual and polypharmacological targeting of BET and non-BET proteins, thus given rise to inhibitors modulating various disease pathways, creating novel phenotypic output, and providing a better understanding as to the individual roles of chromatin-associated proteins in human physiology and disease.

Cambridge Healthtech Institute's Third Annual Targeting Epigenetic Readers and Chromatin Remodelers meeting will once again unite academic and industry researchers for the development of chemical probes to further our understanding of the therapeutic opportunities associated with targeting reader domains and chromatin remodelers.

Who should attend: Executives, Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oncology Drug Discovery, Research and Development, Molecular/Cell Biology, Biochemistry, Chemical Genomics/Biology, Structural Biology, Medicinal Chemistry, Pharmacology and Synthetic Chemistry.

Topics will include, but are not limited to: 

  • Target Identification and Validation
    • Targeting Chromatin Remodelers, BET and Non-BET bromodomains, PhD, Tudor, Chromo, PWWP and MBT domains
    • Novel Reader Targets with Therapeutic Implications in Cancer
    • Selective Inhibition of Readers/Remodelers and Cellular Response
    • Addressing Undesired Consequences of Inhibition
  • Discovery to Lead
    • Structural Characterization of Reader Domains and Remodeler Subunits
    • High-Throughput Profiling and Screening for Inhibitors
    • Virtual Screening
    • Phenotypic Screening
    • Fragment/Structure-Based Design
    • Protein-Protein Interaction Strategies
    • Development of High-Quality Chemical Probes/Scaffolds
    • Discovery of Novel BET and Non-BET inhibitors
    • Lead Optimization
    • Dual Inhibitors
  • Pre-Clinical and Clinical Development
    • Updates on BET Bromodomain Programs in Preclinical and Clinical Stages
    • Disease Relevant Pre-Clinical Models and Biomarkers

If you are interested in speaking, click here to submit a speaking proposal.

The deadline for submission is March 11, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For questions or suggestions about the meeting, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon 

2014 Discovery on Target Brochure  

2014 BROCHURE 

PREMIER SPONSOR 

Cellecta 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000